A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $24 to $75
Tandem Diabetes Care First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Positive Outlook for Tandem Diabetes Care With Strong Recovery and Growth Opportunities
Tandem Diabetes Care Reports Record Sales and Strategic Growth
Research Alert: CFRA Lowers Opinion On Shares Of Tandem Diabetes Care, Inc. To Hold From Buy
Tandem Diabetes Care Price Target Raised to $59.00/Share From $58.00 by Canaccord Genuity
Tandem Diabetes Jumps as Overseas Sales Drive Q1 Beat
$TNDM Stock Is up 14% Today. Here's What We See in Our Data.
Tandem Diabetes Care Is Maintained at Overweight by Piper Sandler
Tandem Diabetes Shares Are Trading Higher After the Company Reported Q1 Financial Results and Beat Its EPS and Revenue Estimates.
Express News | Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $24
Tandem Diabetes Care Analyst Ratings
Express News | Tandem Diabetes Care Inc : Stifel Cuts Target Price to $31 From $60
Express News | Tandem Diabetes Care, Inc. : Wells Fargo Cuts Target Price to $20 From $22
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $27
Earnings Call Summary | Tandem Diabetes Care(TNDM.US) Q1 2025 Earnings Conference
Tandem Diabetes Care Highlights Potential for Type 2 Diabetes Market Growth With Control-IQ+
After-market Movers: Nasdaq 100 Futures Rise More Than 1% on Microsoft, Meta
Tandem Diabetes Care GAAP EPS of -$1.97 Misses by $1.35, Revenue of $234.4M Beats by $14.18M
Express News | Tandem Diabetes Care Affirms FY2025 Sales Guidance of $997.00M-$1.01B Vs $999.58M Est